House of Commons
As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.
FETAL VALPROATE SYNDROME
EDM #1021
Tabled 05 February 2013
2012-13 Session
That this House notes with concern the withdrawal of public funding from the Fetal Anti-Convulsant Litigation in November 2010; further notes that the taxpayer is now covering the additional health, education and welfare costs incurred by families affected by fetal valproate syndrome; believes the Department of Health and the Medicines and Healthcare products Regulatory Agency could have avoided the large numbers of people affected, since the drug sodium valproate came onto the market in the late 1970s, by informing patients treated with anti-convulsant medications and women of child-bearing age; and calls for an independent inquiry into why information has been withheld from the public concerning the disastrous way in which sodium valproate has affected pregnant women and their children.

Signatures (33)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
There are no withdrawn signatures for this Motion